WO2004103403A1 - 免疫担当細胞活性化阻害剤およびその用途 - Google Patents
免疫担当細胞活性化阻害剤およびその用途 Download PDFInfo
- Publication number
- WO2004103403A1 WO2004103403A1 PCT/JP2004/007321 JP2004007321W WO2004103403A1 WO 2004103403 A1 WO2004103403 A1 WO 2004103403A1 JP 2004007321 W JP2004007321 W JP 2004007321W WO 2004103403 A1 WO2004103403 A1 WO 2004103403A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- immunocompetent
- cell activation
- immunocompetent cell
- antibody
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title claims abstract description 46
- 230000020411 cell activation Effects 0.000 title claims abstract description 44
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 52
- 239000003814 drug Substances 0.000 claims abstract description 33
- 229940124597 therapeutic agent Drugs 0.000 claims abstract description 29
- 201000010099 disease Diseases 0.000 claims abstract description 28
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 28
- 238000000034 method Methods 0.000 claims abstract description 26
- 239000012634 fragment Substances 0.000 claims abstract description 24
- 239000004480 active ingredient Substances 0.000 claims abstract description 9
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 7
- 208000006673 asthma Diseases 0.000 claims abstract description 6
- 206010025135 lupus erythematosus Diseases 0.000 claims abstract description 6
- 208000005069 pulmonary fibrosis Diseases 0.000 claims abstract description 6
- 208000011775 arteriosclerosis disease Diseases 0.000 claims abstract description 5
- 206010003210 Arteriosclerosis Diseases 0.000 claims abstract description 4
- 210000004027 cell Anatomy 0.000 claims description 72
- 208000006454 hepatitis Diseases 0.000 claims description 47
- 231100000283 hepatitis Toxicity 0.000 claims description 46
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 37
- 210000000440 neutrophil Anatomy 0.000 claims description 37
- 210000000581 natural killer T-cell Anatomy 0.000 claims description 35
- 230000004913 activation Effects 0.000 claims description 34
- 206010067125 Liver injury Diseases 0.000 claims description 22
- 231100000234 hepatic damage Toxicity 0.000 claims description 19
- 230000008818 liver damage Effects 0.000 claims description 19
- 238000004519 manufacturing process Methods 0.000 claims description 14
- 230000001404 mediated effect Effects 0.000 claims description 14
- 108010044426 integrins Proteins 0.000 claims description 12
- 102000006495 integrins Human genes 0.000 claims description 12
- 230000003013 cytotoxicity Effects 0.000 claims description 9
- 231100000135 cytotoxicity Toxicity 0.000 claims description 9
- 210000003494 hepatocyte Anatomy 0.000 claims description 9
- 230000017074 necrotic cell death Effects 0.000 claims description 7
- 108010031258 SVVYGLR peptide Proteins 0.000 claims description 6
- 210000004898 n-terminal fragment Anatomy 0.000 claims description 6
- 206010003246 arthritis Diseases 0.000 claims description 5
- 230000005779 cell damage Effects 0.000 claims description 5
- 208000037887 cell injury Diseases 0.000 claims description 5
- 201000006417 multiple sclerosis Diseases 0.000 claims description 5
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims description 3
- 206010019799 Hepatitis viral Diseases 0.000 claims description 3
- 201000001862 viral hepatitis Diseases 0.000 claims description 3
- 208000008964 Chemical and Drug Induced Liver Injury Diseases 0.000 claims description 2
- 206010072268 Drug-induced liver injury Diseases 0.000 claims description 2
- 201000008865 drug-induced hepatitis Diseases 0.000 claims description 2
- 102000004264 Osteopontin Human genes 0.000 claims 1
- 108010081689 Osteopontin Proteins 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 abstract description 7
- 208000019423 liver disease Diseases 0.000 abstract description 3
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 208000034189 Sclerosis Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 102100040557 Osteopontin Human genes 0.000 description 86
- 210000004185 liver Anatomy 0.000 description 47
- 230000002401 inhibitory effect Effects 0.000 description 41
- 241000699666 Mus <mouse, genus> Species 0.000 description 36
- 241000699670 Mus sp. Species 0.000 description 34
- 238000001994 activation Methods 0.000 description 31
- 238000004458 analytical method Methods 0.000 description 17
- 238000012360 testing method Methods 0.000 description 14
- 230000000694 effects Effects 0.000 description 13
- 150000001875 compounds Chemical class 0.000 description 12
- 210000000265 leukocyte Anatomy 0.000 description 12
- 230000012292 cell migration Effects 0.000 description 11
- 238000005259 measurement Methods 0.000 description 11
- 239000012228 culture supernatant Substances 0.000 description 10
- 230000005764 inhibitory process Effects 0.000 description 10
- 238000002965 ELISA Methods 0.000 description 9
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 9
- 108090000190 Thrombin Proteins 0.000 description 9
- 229920001222 biopolymer Polymers 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 238000010172 mouse model Methods 0.000 description 9
- 229960004072 thrombin Drugs 0.000 description 9
- 230000002950 deficient Effects 0.000 description 8
- 230000000692 anti-sense effect Effects 0.000 description 7
- 108010024069 integrin alpha9 Proteins 0.000 description 7
- 210000002540 macrophage Anatomy 0.000 description 7
- 241000272875 Ardeidae Species 0.000 description 6
- 108010047761 Interferon-alpha Proteins 0.000 description 6
- 102000006992 Interferon-alpha Human genes 0.000 description 6
- 150000008065 acid anhydrides Chemical class 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 230000003834 intracellular effect Effects 0.000 description 6
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 101100518500 Homo sapiens SPP1 gene Proteins 0.000 description 5
- 108010041012 Integrin alpha4 Proteins 0.000 description 5
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 5
- 108091005804 Peptidases Proteins 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 238000007796 conventional method Methods 0.000 description 5
- 230000008595 infiltration Effects 0.000 description 5
- 238000001764 infiltration Methods 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 108050002982 RuvB-like helicase 1 Proteins 0.000 description 4
- 239000007822 coupling agent Substances 0.000 description 4
- 238000012303 cytoplasmic staining Methods 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- -1 ethyl ethyl Chemical group 0.000 description 4
- 210000004408 hybridoma Anatomy 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 230000005012 migration Effects 0.000 description 4
- 238000013508 migration Methods 0.000 description 4
- 230000001338 necrotic effect Effects 0.000 description 4
- 230000035484 reaction time Effects 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- 238000003436 Schotten-Baumann reaction Methods 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 238000012744 immunostaining Methods 0.000 description 3
- 230000003308 immunostimulating effect Effects 0.000 description 3
- 108700027921 interferon tau Proteins 0.000 description 3
- 102000013415 peroxidase activity proteins Human genes 0.000 description 3
- 108040007629 peroxidase activity proteins Proteins 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 229960002175 thyroglobulin Drugs 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- NFDXQGNDWIPXQL-UHFFFAOYSA-N 1-cyclooctyldiazocane Chemical compound C1CCCCCCC1N1NCCCCCC1 NFDXQGNDWIPXQL-UHFFFAOYSA-N 0.000 description 2
- QDFXRVAOBHEBGJ-UHFFFAOYSA-N 3-(cyclononen-1-yl)-4,5,6,7,8,9-hexahydro-1h-diazonine Chemical compound C1CCCCCCC=C1C1=NNCCCCCC1 QDFXRVAOBHEBGJ-UHFFFAOYSA-N 0.000 description 2
- WADSJYLPJPTMLN-UHFFFAOYSA-N 3-(cycloundecen-1-yl)-1,2-diazacycloundec-2-ene Chemical compound C1CCCCCCCCC=C1C1=NNCCCCCCCC1 WADSJYLPJPTMLN-UHFFFAOYSA-N 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 102000011632 Caseins Human genes 0.000 description 2
- 108010076119 Caseins Proteins 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 238000011891 EIA kit Methods 0.000 description 2
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 2
- 108010039471 Fas Ligand Protein Proteins 0.000 description 2
- 101150112014 Gapdh gene Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 2
- 101000694550 Homo sapiens RuvB-like 1 Proteins 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 102000006386 Myelin Proteins Human genes 0.000 description 2
- 108010083674 Myelin Proteins Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- 102000006381 STAT1 Transcription Factor Human genes 0.000 description 2
- 108010044012 STAT1 Transcription Factor Proteins 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 108010071390 Serum Albumin Proteins 0.000 description 2
- 102000007562 Serum Albumin Human genes 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 102000009843 Thyroglobulin Human genes 0.000 description 2
- 108010034949 Thyroglobulin Proteins 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 150000007514 bases Chemical class 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000012973 diazabicyclooctane Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 231100000753 hepatic injury Toxicity 0.000 description 2
- 102000048385 human RUVBL1 Human genes 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 210000005228 liver tissue Anatomy 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000001617 migratory effect Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000005012 myelin Anatomy 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 101100447462 Brugia malayi G3PD gene Proteins 0.000 description 1
- 102000005701 Calcium-Binding Proteins Human genes 0.000 description 1
- 108010045403 Calcium-Binding Proteins Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- 240000004244 Cucurbita moschata Species 0.000 description 1
- 235000009854 Cucurbita moschata Nutrition 0.000 description 1
- 235000009852 Cucurbita pepo Nutrition 0.000 description 1
- 241000975394 Evechinus chloroticus Species 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 108010020382 Hepatocyte Nuclear Factor 1-alpha Proteins 0.000 description 1
- 102100022057 Hepatocyte nuclear factor 1-alpha Human genes 0.000 description 1
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102100039903 Integrin alpha-9 Human genes 0.000 description 1
- 102100022338 Integrin alpha-M Human genes 0.000 description 1
- 208000029523 Interstitial Lung disease Diseases 0.000 description 1
- 102000015617 Janus Kinases Human genes 0.000 description 1
- 108010024121 Janus Kinases Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930191564 Monensin Natural products 0.000 description 1
- GAOZTHIDHYLHMS-UHFFFAOYSA-N Monensin A Natural products O1C(CC)(C2C(CC(O2)C2C(CC(C)C(O)(CO)O2)C)C)CCC1C(O1)(C)CCC21CC(O)C(C)C(C(C)C(OC)C(C)C(O)=O)O2 GAOZTHIDHYLHMS-UHFFFAOYSA-N 0.000 description 1
- 210000004460 N cell Anatomy 0.000 description 1
- JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 102100035593 POU domain, class 2, transcription factor 1 Human genes 0.000 description 1
- 101710084414 POU domain, class 2, transcription factor 1 Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 108050002568 Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 238000005282 brightening Methods 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 230000013929 chemokine (C-X-C motif) ligand 2 production Effects 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- UQHKFADEQIVWID-UHFFFAOYSA-N cytokinin Natural products C1=NC=2C(NCC=C(CO)C)=NC=NC=2N1C1CC(O)C(CO)O1 UQHKFADEQIVWID-UHFFFAOYSA-N 0.000 description 1
- 239000004062 cytokinin Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000005243 fluidization Methods 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 108060003552 hemocyanin Proteins 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 230000011488 interferon-alpha production Effects 0.000 description 1
- 230000010815 interferon-tau production Effects 0.000 description 1
- 230000017307 interleukin-4 production Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 231100000832 liver cell necrosis Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- QQHNGZNHRRLNKI-UHFFFAOYSA-N methyl carbonobromidate Chemical compound COC(Br)=O QQHNGZNHRRLNKI-UHFFFAOYSA-N 0.000 description 1
- XMJHPCRAQCTCFT-UHFFFAOYSA-N methyl chloroformate Chemical compound COC(Cl)=O XMJHPCRAQCTCFT-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- XONPDZSGENTBNJ-UHFFFAOYSA-N molecular hydrogen;sodium Chemical compound [Na].[H][H] XONPDZSGENTBNJ-UHFFFAOYSA-N 0.000 description 1
- 229960005358 monensin Drugs 0.000 description 1
- GAOZTHIDHYLHMS-KEOBGNEYSA-N monensin A Chemical compound C([C@@](O1)(C)[C@H]2CC[C@@](O2)(CC)[C@H]2[C@H](C[C@@H](O2)[C@@H]2[C@H](C[C@@H](C)[C@](O)(CO)O2)C)C)C[C@@]21C[C@H](O)[C@@H](C)[C@@H]([C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O2 GAOZTHIDHYLHMS-KEOBGNEYSA-N 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 229940086066 potassium hydrogencarbonate Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 229940080237 sodium caseinate Drugs 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 235000020354 squash Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/10—Expectorants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Definitions
- the present invention relates to an immunocompetent cell activation inhibitor containing an antibody against genius pontin or a fragment peptide portion thereof, and use thereof.
- Immunocompetent cells such as B cells, macrophages, dendritic cells, T cells, NKT cells, and neutrophils are involved in the immune system in the body.
- liver damage Kaneko Y., et al., J. Exp. Med., 2000, Jan 3; 191 (1): 105-14, Nakamura K., et a, J. Hepatol., 2001, Aug; 35 (2): 217-24, Tiegs G., et a, J. Cl in .. Invest. 1992 Jul; 90 (1): 196-203
- asthma Akbari 0., et al., Nat. Med., 2003, May; 9 (5): 582-8, Linden A., Int. Arch.
- an object of the present invention is to provide a drug capable of treating the above-mentioned diseases.
- Inhibitory antibody J is used for the treatment of autoimmune diseases, rheumatoid arthritis and rheumatoid arthritis (W 00 2/08 152 2 pamphlet and WO 03/0 2 7 15 1 pamphlet), tuberculosis diagnosis Agent (JP-A-2003-294735), an agent for preventing tendon and ligament deterioration (Japanese Patent Application No. 2003-389543), a diagnostic agent for interstitial pneumonia (Japanese Patent Application No. 2003-194977), etc. He has filed a patent application first.
- OPN-inhibiting antibody can be used as a therapeutic agent for diseases caused by activation of immunocompetent cells, and completed the present invention.
- the present invention is as follows.
- An immunocompetent cell activation inhibitor containing an antibody against a genius pontin or a fragment peptide portion thereof.
- a therapeutic agent for a disease caused by activation of immunocompetent cells comprising the immunocompetent cell activation inhibitor according to any one of (1) to (14) as an active ingredient.
- immunocompetent cell is one or more of immunocompetent cells selected from NKT cells, neutrophils, and T cells.
- the disease caused by activation of immunocompetent cells is a disease selected from hepatitis, asthma, arthritis, diabetes, lupus, multiple sclerosis, arteriosclerosis, pulmonary fibrosis (15) or (16) The therapeutic agent for the disease described in (16).
- a therapeutic agent for liver damage comprising the immunocompetent cell activation inhibitor according to any one of (1) to (14) as an active ingredient.
- liver disorder The therapeutic agent for liver disorder according to (18), wherein the liver disorder is viral hepatitis or drug-induced hepatitis.
- liver damage The therapeutic agent for liver damage according to (18), wherein the liver damage is autoimmune hepatitis.
- (22) A method for treating a disease caused by activation of immunocompetent cells, comprising administering the therapeutic agent according to any one of (15) to (17) to a patient having the disease caused by activation of immunocompetent cells.
- FIG. 1 is a drawing showing ALT values in serum.
- FIG. 2 is a drawing of hepatitis tissue stained with HE.
- FIG. 3 is a drawing showing the ratio of the number of necrotic cells in the microscopic field of hepatitis tissue.
- FIG. 4 is a drawing showing the expression level of OPN in the liver in a hepatitis model mouse.
- FIG. 5 is a drawing showing the results of a Western plot of the hepatitis model mouse. Arrows indicate trombin-cleaved OPN.
- FIG. 6 is a drawing showing ALT values in serum of wild-type mice and 0PN-deficient mice after ConA administration.
- FIG. 7 is a drawing showing the survival rates of wild-type mice and 0PN-deficient mice after administration of ConA.
- Fig. 8 is a drawing showing the results of intracellular cytoplasmic staining of hepatitis model mice.
- the left figure shows the results of staining lymphocytes in leukocytes in liver with anti-NK1.1 antibody and TCR antibody.
- the middle figure (R 1) shows the NKT cell population fraction of NK1.1 + TCR +
- the right figure (R 2) shows the OPN generation in the T cell population fraction of NK1.1-TCR +.
- the result of FACS analysis is shown below.
- Fig. 9 is a drawing showing the results of ELISA for measuring the OPN levels in cell culture supernatants of NKT cells and T cells isolated from the liver of a hepatitis model mouse.
- Fig. 10 shows the liver of a hepatitis model mouse.
- 3 is a drawing showing the results obtained by amplifying mRNA extracted from NKT cells and T cells isolated from the inside by RT-PCR, and detecting the OPN receptor and MIP-2 possessed by each cell.
- FIG. 11 is a drawing showing the results of a cell migration test on trombin-cleaved OPN of liver-infiltrating leukocytes obtained from a hepatitis model mouse and a wild-type mouse.
- FIG. 12 is a drawing showing the results of a cell migration inhibition test on thrombin-cleaved OPN of liver-infiltrating leukocytes obtained from a hepatitis model mouse.
- Figure 1 3 is a diagram surface showing the in the liver of hepatitis model mice, the percentage of CD 6 9 + CD 4 + T cells during M 5 antibody and control antibody administration results of the FACS analysis.
- Fig. 14 shows the number of activated CD4 + T cells calculated from the results of analysis of the number of CD69 + 004 + cells after administration of the M5 antibody and control antibody in the liver of a hepatitis model mouse.
- Figure 15 shows FACS analysis of neutrophils, CD4 + T cells, and macrophages in liver infiltrating cells 6 hours after administration of ConA to wild-type mice and 0 PN-deficient mice, respectively. 6 is a drawing showing the results calculated in FIG.
- Figure 16 shows the results of staining liver tissue 24 hours after administration of C0 ⁇ A to wild-type mice.
- the left figure shows the results of immunostaining using the MP0 antibody.
- the right figure shows the result of HE staining.
- Figure 17 shows MPO activity in the culture supernatant of wild-type mice in which full-length OPN, N-half OPN, and C-half PN were added to neutrophils separated by intraperitoneal administration of sodium caseinate. is there.
- FIG. 18 is a drawing showing the result of calculating the neutrophil count in liver 6 hours after administration of ConA to wild-type mice by FACS analysis.
- FIG. 19 is a drawing showing the time course of MIP-2 concentration after administration of C0nA to wild-type mice.
- FIG. 20 is a drawing showing the results of quantifying the expression levels of Nana, a9 integu and J mRNA in the liver after administration of ConA to wild-type mice by real-time PCR (black circles). Is a graph of control antibody administration, and a white circle is a graph after administration of M5 antibody.)
- FIG. 21 is a drawing showing the result of measuring the amount of IFN in the culture supernatant of NKT cells and T cells of mouse liver by the ELISA method.
- Figure 22 shows the IFN- ⁇ expression levels in the liver of C on A hepatitis mice to which the M5 antibody was administered and C 0 n A hepatitis mice to which the control antibody was administered.
- 3 is a drawing showing the results of quantification using the method described in US Pat.
- FIG. 23 is a drawing comparing the ALT values obtained when 400 Atg of the M5 antibody was administered to each mouse 3 hours before administration of ConA and simultaneously with the administration of C0nA.
- the immunocompetent cell activation inhibitor of the present invention (hereinafter referred to as “the inhibitor of the present invention”) is an antibody against OPN or a fragment peptide portion thereof (hereinafter referred to as “ ⁇ ⁇ , etc.”) (OPN inhibitory antibody). It is prepared by combining the active ingredient with an appropriate pharmaceutically acceptable carrier ingredient.
- the 0 PN inhibitory antibody used in the present invention can be used without particular limitation as long as it recognizes 0 P N and the like.
- Such 0 PN inhibitory antibodies include an integrin that recognizes the RGD sequence and an integrin that recognizes the SVVYGLR sequence while inhibiting the binding between 0 PN and the like.
- integrins that recognize the RGD sequence such as Q! V j81, av i83, ⁇ ; or inhibit the binding of their N-terminal fragment, and recognizes the SVVYGLR sequence integrin, for example ⁇ 9 ⁇ 4 ⁇ ⁇ , ⁇ 4 ⁇ 7 or the like and OPN- a, OPN- b, OPN- c or their Those that inhibit binding to the N-terminal fragment are preferred.
- the N-terminal fragment refers to a fragment on the N-terminal side among fragments obtained by degrading OPN by a protease.
- An example of the proteolytic enzyme is trombin.
- the above 3 ⁇ ⁇ 0 sequence is a sequence from serine 162 to arginine 168 of human OPN (accession number: J04765).
- the production method of the OPN-inhibiting antibody in the present invention is not particularly limited as long as it retains the above properties.
- OPN-a, OPN-b, OPN-c, N-terminal fragment thereof, or Those prepared by using, as an antigen, a peptide containing the amino acid sequence represented by the following (A) or a corresponding sequence thereof (hereinafter, these are collectively referred to as "related peptides”) can be used.
- the above-mentioned equivalent sequence refers to a sequence corresponding to the sequence (SVVYGLR) from serine No. 16 to arginine No. 168 of human OPN at 0 PN of an animal other than human, for example, Pigs have the same SVVYGLR as the humans, monkeys have the SVAYGLR, monkeys have the SLAYGLR, males have a stomach of 500 to 1, and males have the SVAYRLK.
- Preferred OPN-inhibiting antibodies for humans are produced, for example, by using a peptide containing the sequence of the above (A) as an antigen. More preferably, for example, the sequence from the valine residue at position 15 to the serine residue at position 169 of 0PN-a (accession number: J04765) having both of these sequences consecutively is preferable. It can be obtained by using peptide (B) as an antigen and treating it according to a conventional method.
- V DT YDGRGDSVVYGLRS (SEQ ID NO: 2)
- B a conjugate of the peptide and a biopolymer compound as the antigen.
- the biopolymer compound to be bound to the 0PN-related peptide include squash shell hemocyanin (hereinafter referred to as “KLH”), ovalbumin (hereinafter referred to as “roVAj”), and ⁇ serum albumin (hereinafter referred to as “BS AJ”).
- KLH squash shell hemocyanin
- roVAj ovalbumin
- BS AJ ⁇ serum albumin
- RSA Egret serum albumin
- thyroglobulin thyroglobulin
- the binding between the OPN-related peptide and the biopolymer compound can be performed, for example, by the mixed anhydride method (BF Erlanger et al., (1954): J. Biol. Chem., 234, 1090-1094) or an activated ester. (AE Karu et a, (1994): J. Agric. Food Chem., 42, 301-309).
- the mixed acid anhydride used in the mixed acid anhydride method is obtained by subjecting an OPN-related peptide to a usual Schotten-Baumann reaction, and reacting this with a biopolymer compound to obtain the desired peptide.
- a polymer compound conjugate is produced.
- the haloformate used in the mixed acid anhydride method include methyl chloroformate, methyl bromoformate, ethyl ethyl chloroformate, ethyl ethyl bromoformate, isobutyl chloroformate and the like.
- the ratio of the peptide, the haloformate and the polymer compound used in the method can be appropriately selected from a wide range.
- the Schotten-Baumann reaction is performed in the presence of a basic compound.
- the basic compound used in the reaction include compounds commonly used in the Schotten-Baumann reaction, such as triethylamine, trimethylamine, pyridine, and the like.
- Organic bases such as dimethylaniline, N-methylmorpholine, diazabicyclononene (DBN), diazabicycloundecene (DBU), diazabicyclooctane (DABCO), potassium carbonate, sodium carbonate, potassium hydrogen carbonate, carbonate
- An inorganic base such as sodium hydrogen can be used.
- the above reaction is usually carried out at a temperature of from 20 ° C. to 100 ° C., preferably from 0 ° C. to 50 ° C., and the reaction time is about 5 minutes to 10 hours, preferably 5 minutes to 2 hours. It is.
- the reaction between the obtained mixed acid anhydride and the biopolymer compound is usually performed at minus 20 ° C.
- the reaction is carried out at 150 ° C., preferably at 0 ° C. to 100 ° C., and the reaction time is about 5 minutes to 10 hours, preferably 5 minutes to 5 hours.
- the mixed acid anhydride method is generally carried out in a solvent, but any solvent commonly used in the mixed acid anhydride method can be used as the solvent, and specifically, dichloromethane, chloroform, dichloroethane, etc.
- Halogenated hydrocarbons aromatic hydrocarbons such as benzene, toluene, xylene, etc., ethers such as getyl ether, dioxane, tetrahydrofuran, and dimethoxetane; esters such as methyl acetate, ethyl acetate; Aprotic polar solvents such as N-dimethylformamide, dimethylsulfoxide, and hexamethylphosphoric triamide;
- the activated ester method can be generally performed as follows. First, an OPN-related peptide is dissolved in an organic solvent and reacted with N-hydroxysuccinimide in the presence of a coupling agent to form an N-hydroxysuccinimide-activated ester.
- the force coupling agent a usual force coupling agent commonly used in a condensation reaction can be used, and examples thereof include dicyclohexylcarpoimide, carbonyldiimidazole, and water-soluble carpoimide.
- the organic solvent for example, N, N-dimethylformamide (DMF), dimethylsulfoxide, dioxane and the like can be used.
- the molar ratio of the peptide used for the reaction to the coupling agent such as N-hydroxysuccinimide is preferably 1:10 to 10: 1, most preferably 1: 1.
- the reaction temperature is 0 to 50 ° C, preferably 22 to 27 ° C, and the reaction time is 5 minutes to 24 hours, preferably 1-2 hours.
- the reaction can be carried out at a temperature from the melting point to the boiling point.
- reaction temperature is 0 to 60 ° C, preferably 5 to 40 ° C, more preferably 22 to 27 ° C, and the reaction time is 5 minutes to 24 hours, preferably 1 to 16 hours. The time is more preferably 1-2 hours.
- the reaction product of the OPN-related peptide and the biopolymer compound By purifying the reaction product of the OPN-related peptide and the biopolymer compound by the above method using a dialysis, desalting column or the like, the 0 PN-related peptide and the biopolymer can be purified.
- conjugate with the compound (hereinafter sometimes simply referred to as a “conjugate”) can be obtained.
- an animal in order to prepare the polyclonal antibody of the present invention using the above conjugate, an animal may be immunized with the conjugate and the antibody may be collected from the animal.
- a conjugate such as an OPN-related peptide-thyroglobulin conjugate is dissolved in sodium phosphate buffer (hereinafter referred to as “PBS”), and this is combined with Freund's complete adjuvant or Freund's incomplete adjuvant.
- PBS sodium phosphate buffer
- a mammal is immunized using a mixture of a mouse or an adjuvant such as alum as an immunogen.
- any animal commonly used in the art can be used, and examples thereof include a mouse, a rat, a rabbit, a goat, and a rabbit.
- the method of administering the immunogen upon immunization may be any of subcutaneous injection, intraperitoneal injection, intravenous injection and intramuscular injection, but subcutaneous injection or intraperitoneal injection is preferred. Immunization can be performed once or multiple times at appropriate intervals, preferably multiple times at intervals of 1 to 5 weeks.
- OPN inhibitory antibodies can be obtained by collecting blood from the immunized animal, separating serum, and purifying the polyclonal antibody fraction according to a conventional method.
- An OPN inhibitory antibody can also be obtained as a monoclonal antibody by obtaining a hybridoma by fusing immunocytes obtained by immunizing an animal with the product and myeloma cells, and collecting an antibody from a culture of the hybridoma.
- the above-mentioned OPN inhibitory antibody is genetically modified by a conventional method so that the constant region of the antibody has the same constant region as that of the human antibody to be treated, and the chimeric antibody (European Patent Publication EP 0 1 ⁇ As a humanized antibody (see European Patent Publication EP 0 239 400 or EP 0 415 126, International Publication WO 03 027 151) Is also good.
- the OPN inhibitory antibody thus obtained can be used in the form of Fv, & 13 & (ab ') 2 in which the antigen-recognition region has been cut out with a protease or the like.
- an OPN inhibitory antibody corresponding to the mouse OPN is preferably an RGDSLAYGLR sequence. It is produced by using a peptide containing as an antigen.
- the inhibitor of the present invention described above contains the above 0PN inhibitory antibody as an active ingredient. By combining this with a pharmaceutically acceptable carrier and formulating it in a conventional manner, the immunocompetent cell A therapeutic agent for a disease caused by activation (hereinafter referred to as "the therapeutic agent of the present invention”) is obtained.
- the dose of the 0 PN inhibitory antibody to the patient in the therapeutic agent of the present invention varies depending on the severity of the patient's condition, age, dosage form of the preparation to be used, or the binding titer of the antibody. 1 to "! About 0. 0 mg / kg, preferably about 0.5 to 80 mg Z kg. Therefore, it is preferable to formulate the drug in an amount suitable for this.
- the mold include parenteral preparations such as injections and ophthalmic preparations, to which other optional ingredients usually used in the production of pharmaceutical compositions are added as long as the effects of the present invention are not impaired.
- Such optional components include, for example, adsorbents, preservatives, antioxidants, buffers, chelating agents, coloring agents, emulsifiers, flavoring / flavoring agents, curing agents, surfactants, and suspensions. Agents, sweeteners, lubricants, excipients, coating agents, fluidization , Brightening agents, tonicity agents, binders, bulking agents, etc.
- the immunocompetent cells whose activation is inhibited by the inhibitor of the present invention thus obtained include macrophages, T cells, NKT cells, Among these immunocompetent cells, it preferably inhibits the activation of T cells, NKT cells, and neutrophils, and the inhibitor of the present invention is caused by the activation of the immunocompetent cells. Inhibition of Fas / FasL cell damage and neutrophil-mediated cell damage.
- the disease treated or improved by the therapeutic agent of the present invention is not particularly limited.
- examples include liver injury, asthma, arthritis, diabetes, lupus, multiple sclerosis, arterial sclerosis, pulmonary fibrosis, and the like.
- the therapeutic agent of the present invention can suitably suppress liver cell necrosis among these diseases, so that it is an effective treatment for liver damage such as viral hepatitis and drug-resistant hepatitis, especially for acute liver damage such as autoimmune hepatitis.
- Be a medicine Although the mechanism of action of the inhibitor or therapeutic agent of the present invention is unknown, it is believed that activation of immunocompetent cells directly or indirectly caused by 0PN degraded by OPN or proteolytic enzymes, etc.
- Antibodies to OPN, OPN, etc. are considered to be inhibited.
- liver injury As a specific example.
- ConA concanapalin A
- NKT cells in the liver produce OPN as shown in the Examples below.
- the OPN produced here is decomposed by a proteolytic enzyme or the like to become a 0PN fragment peptide.
- 0PN or the like activates NKT cells in an autocrine manner, 1 ⁇ 1 cells produce 1FN- ⁇ . It is known that this IFN-a has the following effects (Hong F., et al., J. Clin. Invest. 2002 Nov; 110 (10): 1503-13).
- NKT cells produce IL-14 when activated (Kaneko ⁇ ⁇ , et al., J. Exp. Med., 2000, Jan 3; 191 (1): 105 -14), then I One-
- N4 acts on NK T cells in a highly selective manner, and as a result, NK T cells express the F a s ligand. And NKT cells will cause FasZFasL-mediated cytotoxicity to hepatocytes.
- NK T cells by the activation of NK T cells by the above-described OPN or the like, NK T cells produce MIP-2 (Macrophageinef Iammato.ryprotine-2). This MIP-2 is known to promote neutrophil migration and accumulation (Xiao YQ., Et al., Biochim. Biophys. Acta. 1997 Aug 22: 1361 (2): 138-46.) As a result, active oxygen produced by neutrophils causes damage to hepatocytes (neutrophil-mediated cytotoxicity).
- an OPN-inhibiting antibody which is an active ingredient of the inhibitor or therapeutic agent of the present invention, binds to OPN or a fragment peptide portion thereof, and is activated by OPN or the like. It can inhibit the activation of immunocompetent cells such as neutrophils.
- the OPN inhibitory antibody can also inhibit IFN-cell production, MIP-2 production, and I-IV production of NKT cells by inactivating immunocompetent cells as described above. .
- the 0 [ ⁇ inhibitory antibody inhibits the production of 1 ⁇ 1 IP-2, thereby inhibiting neutrophil migration and MPO production, and subsequent neutrophil-mediated cytotoxicity. Can be.
- VDTYDGRGDSVVYGLRS SEQ ID NO: 2
- This 2 peptide has an RGD and SVVYGL sequence that recognizes avj83 and ⁇ 9) 81 integrin receptor.
- the 2-1 peptide was bound to thyroglobulin, which was used to immunize mice according to a conventional method.
- the method selected eightybri dorma. Selection was performed by selecting a hybridoma that responded to immobilized GST / 0PNa and 0PNa—a derived from CHO cells, but did not appear to respond to GST.
- OPN inhibitory antibody was administered to a hepatitis model mouse artificially prepared by administering ConA to a wild-type mouse, and the effect was confirmed.
- the 2K1 antibody against human OPN cannot be used as it is. Therefore, it corresponds to the internal sequence (C + V138 to R153) of the following mouse genius bontin having the SLAYGLR sequence of mouse OPN corresponding to the SV VY GLR sequence of human OPN and the RGD sequence.
- a synthetic peptide (M5 peptide) was prepared, and an M5 antibody was produced and used in the same manner as in Example 1.
- M5 peptide C V D V P N G R G D S L A Y G L R (SEQ ID NO: 3)
- M5 antibody was intravenously administered to BAL BZc mice (6 weeks old, female), which had been fasted overnight, at 400 At mice 3 hours before administration of ConA.
- the control group received the same volume of Egret IgG. C on A was then administered intravenously in 300 animals.
- Serum was collected 2, 6, 12 and 24 hours after M5 antibody administration, and the ALT value in the serum was measured.
- the results are shown in FIG.
- the ratio of the number of necrotic cells in the microscopic field of hepatitis tissue was about 10% for the liver to which the M5 antibody was administered, while 50% for the liver to which the heron IgG was administered. ( Figure 3).
- the ALT value was about 1,500 when the M5 antibody was administered, which was lower than that of the control, which was about 5,000 (Fig. 1).
- the M5 antibody was found to suppress hepatitis necrosis due to hepatitis.
- the M5 antibody against mouse OPN suppressed hepatocyte necrosis, indicating that the 2K1 antibody against human 0 PN can also suppress hepatocyte necrosis due to human hepatitis. did.
- the hepatitis mouse model was prepared by administering 15 mgZ kg of ConA to wild-type mice to the tail vein.
- the expression of 0 PN in the liver of the hepatitis model mouse was determined by ELISA using mO PNELISA kit (manufactured by Immune Biology Laboratories) and an anti-genius steobontin antibody (manufactured by Immune Biology Laboratories). Analysis was performed using the Western blot method.
- Figure 4 shows the results of the ELISA method.
- Figure 5 shows the results of the Western plot.
- ALT levels in serum were measured in the same manner as in 2.
- survival rates after administration of 400 ⁇ g Z of C on ⁇ were compared.
- Figure 6 shows the results of the ALT value measurement. did.
- Figure 7 shows the results of the survival rate.
- liver of a hepatitis model mouse prepared by injecting 300 g of Con A into the tail vein was removed (6 hours), homogenized, and passed through a mesh. Then, after washing with PBS, the cells were added to 33% Percol I containing heparin (1OO UZml) to remove hepatocytes, and treated at 2,000 rpm for 15 minutes to remove the cell pellet. Was prepared. The obtained cell pellet was treated with a red blood cell hemolysis buffer (hereinafter referred to as “HLB solution J”) (manufactured by Immune Biology Laboratories) to lyse the red blood cells, and these were further washed with PBS three times. After washing, liver-infiltrating leukocytes were prepared in addition to D-ME / 10% FCS.
- HLB solution J red blood cell hemolysis buffer
- the liver-infiltrating leukocytes prepared in (1) above were cultured for 90 minutes in the presence of monensin, and cell surface molecules were detected with an anti-NK1.1 antibody and an anti-TCR jS antibody (both from PharMingen). Stained. Then, fixed for 10 minutes in 4% paraformaldehyde, saponin buffer permeabilized with (1% FCS, 0. 1% saponin, PBS solution containing 0. 1% N a N 3) was performed. Furthermore, a bitinylated OPN inhibitory antibody (manufactured by Immune Biology Laboratories, Inc.) was added, and streptavidin-APC (manufactured by Jackson) was used as a secondary antibody. iber: BD).
- FIG. 8 shows the results of intracellular cytoplasmic staining of hepatitis model mice.
- FIG. 9 shows the measurement results of the cell culture supernatant by ELISA.
- Intracellular cytoplasmic staining confirmed that OPN was expressed in the cells of the NKT cell population, which is NK1.1 + TCR +.
- OPN expression was detected in the NKT cell population of NK1.1 + TCR + by ELISA measurement of the amount of 0 PN in the cell culture supernatant, but in the T cell population of NK1.1-TCR + No OPN expression was detected.
- OPN-producing cells in the liver were mainly NKT cells.
- a cell migration test was carried out on a thrombin digest of liver infiltrating leukocytes.
- 1 OgZmI of hepatitis-infiltrating leukocytes of the hepatitis model mouse prepared in Example 5 was supplemented with lO ig / ml and trombin (T hr), respectively, with 0 PN (r0PN: uncleaved OPN).
- T hr lO ig / ml and trombin
- 0PN r0PN: uncleaved OPN
- the cell migration effect of cells obtained from a hepatitis model mouse on the thrombin digest of OPN (T hr — OPN) 10 / g / mI was measured using the M5 antibody obtained in Example 2, 1 ⁇ 11 Antibody (0—17) (manufactured by Institute of Immunology), anti-integrin / 31 (HM ⁇ ⁇ ) antibody, anti-) 83 (HMj83) antibody, anti- ⁇ (R ⁇ V-7) )
- the antibody and anti- ⁇ 4 (R ⁇ -2) antibody both manufactured by PharMingen) were inhibited by 100 ⁇ g gZml. The results are shown in FIG.
- FIG. 14 shows the number of activated CD 4 + T cells calculated from the analysis results.
- FIG. 15 shows the calculated numbers of neutrophils, CD 4 + T cells, and macrophages in each mouse.
- Liver tissue obtained from a hepatitis model mouse was embedded in paraffin, sliced into 5 m sections, and treated with endogenous peroxidase. Then, an anti-MPO antibody (manufactured by DAKO) was reacted with the slice as a primary antibody overnight at 4 ° C. Next, immunostaining was performed by reacting ENVISON (made by DAKO) as a secondary antibody.
- Full-length mouse OPN (L17-N294) is cleaved by trombin at R154 and S155, and N-terminal OPN (L17-R154) at the N-terminal end C half-terminal OPN (S155-N294) on the C-terminal side was prepared by the following method to obtain a GST fusion protein.
- the N half OPN and C half OPN were recloned from mouse kidney cDNA by PCR using the following primers (SEQ ID NOS: 12 to 15).
- Full length mouse O P N
- the PCR product obtained using the above primers was digested with restriction enzymes BamHI and XhoI, then introduced into pGEX6P-1 vector-1 (Amersham), and ABI31 The sequence was confirmed using 0 Genetic Analyzer automatic sequencer (Applied Biosystems). Next, this sequence was introduced into Escherichia coli JMl09 to transform Escherichia coli, and the GST-fused 0PN protein was purified by a conventional method.
- MPO myelin peroxidase activity was measured from the culture supernatant in which neutrophils were stimulated with 20 / X g / ml of the GST-fused OPN protein for 36 hours.
- IFN-T in the culture supernatant of NKT cells and T cells isolated from the ConA-administered mice was measured using an IFN- ⁇ EIA kit (Pharmingen). The results are shown in FIG. As a result of analysis of IFN- ⁇ -expressing cells in the liver, it was confirmed that IFN-I was mainly produced from NKT cells.
- NKT cells were the main OPN-producing cells in the hepatitis of mice generated by administering ConA.
- the administration of 0PN inhibitory antibody was found to inhibit the production of IFN- ⁇ and MIP-2, and as a result, it was possible to inhibit the activation of NKT cells.
- NKT cells since activation of NKT cells can be inhibited, it is considered that production of IL-4 can also be inhibited. In addition, it inhibits the activation of CD4 + T cells and neutrophils associated with the activation, It was found that FasZFasL-mediated cytotoxicity and neutrophil-mediated cytotoxicity associated with their activation could also be inhibited.
- mouse OPN-inhibiting antibodies show inhibitory effects on NKT cell activation, CD4 + T cell activation, neutrophil activity, etc., and are caused by the activation of immunocompetent cells. Therefore, it was suggested that a human OPN inhibitory antibody (2K1 antibody) could similarly treat a disease.
- the immunocompetent cell activation inhibitor of the present invention inhibits the activation of immunocompetent cells.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04734385A EP1637159A4 (en) | 2003-05-23 | 2004-05-21 | IMMUNOMETIMENT CELL ACTIVATION INHIBITOR AND ITS USE |
JP2005506423A JPWO2004103403A1 (ja) | 2003-05-23 | 2004-05-21 | 免疫担当細胞活性化阻害剤およびその用途 |
US10/557,602 US20070274993A1 (en) | 2003-05-23 | 2004-05-21 | Immunocompetent Cell Activation Inhibitor and Use Thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003146188 | 2003-05-23 | ||
JP2003-146188 | 2003-05-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004103403A1 true WO2004103403A1 (ja) | 2004-12-02 |
Family
ID=33475292
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/007321 WO2004103403A1 (ja) | 2003-05-23 | 2004-05-21 | 免疫担当細胞活性化阻害剤およびその用途 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20070274993A1 (ja) |
EP (1) | EP1637159A4 (ja) |
JP (1) | JPWO2004103403A1 (ja) |
WO (1) | WO2004103403A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012102100A (ja) * | 2010-11-12 | 2012-05-31 | Chiba Univ | Cd69アンタゴニストを含む肝炎治療用組成物 |
JP5399710B2 (ja) * | 2006-10-26 | 2014-01-29 | 株式会社ジーンテクノサイエンス | 細胞外マトリックスタンパク質のアミノ酸配列rgdに対する抗体およびその製法と用途 |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2429016C2 (ru) * | 2006-05-31 | 2011-09-20 | Астеллас Фарма Инк. | Гуманизированное антитело против остеопонтина человека |
WO2008131094A1 (en) * | 2007-04-17 | 2008-10-30 | Pfizer Inc. | Method for controlling glucose uptake and insulin sensitivity |
CN101293916A (zh) * | 2007-04-24 | 2008-10-29 | 上海国健生物技术研究院 | 骨桥蛋白的功能表位、与其特异性结合的单克隆抗体及用途 |
US8614296B2 (en) | 2008-04-24 | 2013-12-24 | Gene Techno Science Co., Ltd. | Humanized antibodies specific for amino acid sequence RGD of an extracellular matrix protein and the uses thereof |
US8617829B2 (en) | 2009-09-24 | 2013-12-31 | Gene Techno Science Co., Ltd. | Humanized antibodies specific for amino acid sequence RGD of an extracellular matrix protein and the uses thereof |
TW201623329A (zh) * | 2014-06-30 | 2016-07-01 | 亞佛瑞司股份有限公司 | 針對骨調素截斷變異體的疫苗及單株抗體暨其用途 |
EA201992562A1 (ru) * | 2017-05-04 | 2020-07-01 | Фолликум Аб | Пептиды для лечения сахарного диабета |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000063241A2 (en) * | 1999-04-15 | 2000-10-26 | Children's Medical Center Corporation | Methods and compositions for modulating an immune response |
WO2002081522A1 (fr) * | 2001-04-05 | 2002-10-17 | Immuno-Biological Laboratories Co., Ltd. | Anticorps dirigé contre l'ostéopontine, et son utilisation |
WO2003027151A1 (fr) * | 2001-09-25 | 2003-04-03 | Immuno-Biological Laboratories Co., Ltd. | Anticorps recombinant anti-osteopontine et son utilisation |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1269196B1 (en) * | 2000-03-23 | 2007-11-21 | Glaxo Group Limited | Method of screening for inhibitors of osteopontin |
-
2004
- 2004-05-21 WO PCT/JP2004/007321 patent/WO2004103403A1/ja active Application Filing
- 2004-05-21 EP EP04734385A patent/EP1637159A4/en not_active Withdrawn
- 2004-05-21 US US10/557,602 patent/US20070274993A1/en not_active Abandoned
- 2004-05-21 JP JP2005506423A patent/JPWO2004103403A1/ja active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000063241A2 (en) * | 1999-04-15 | 2000-10-26 | Children's Medical Center Corporation | Methods and compositions for modulating an immune response |
WO2002081522A1 (fr) * | 2001-04-05 | 2002-10-17 | Immuno-Biological Laboratories Co., Ltd. | Anticorps dirigé contre l'ostéopontine, et son utilisation |
WO2003027151A1 (fr) * | 2001-09-25 | 2003-04-03 | Immuno-Biological Laboratories Co., Ltd. | Anticorps recombinant anti-osteopontine et son utilisation |
Non-Patent Citations (3)
Title |
---|
HARADA MICHINARI ET AL.: "Valpha14NKT saibo ni yoru shizen men'ekikei to kakutoku men'ekikei no seigyo", PROTEIN, NUCELIC ACID AND ENZYME, vol. 47, no. 16, 2002, pages 2109 - 2116, XP002986899 * |
KATO KAZUNORI: "Men'eki shikkan o meguru kisoteki kenkyu no shinpo killer saibo no saibo shogai kiko", BESSATSU.IGAKU NO AYUMI MEN'EKI SHIKKAN, ISHIAYAKU PUB., 1995, pages 48 - 50, XP002986900 * |
MORIMOTO JUNKO ET AL.: "Osteopontin to men'eki seigyo", ANNUAL REVIEW MEN'EKI 2002, KABUSHIKI KAISHA CHUGAI IGAKUSHA, 2001, pages 151 - 157, XP002987001 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5399710B2 (ja) * | 2006-10-26 | 2014-01-29 | 株式会社ジーンテクノサイエンス | 細胞外マトリックスタンパク質のアミノ酸配列rgdに対する抗体およびその製法と用途 |
JP2012102100A (ja) * | 2010-11-12 | 2012-05-31 | Chiba Univ | Cd69アンタゴニストを含む肝炎治療用組成物 |
Also Published As
Publication number | Publication date |
---|---|
JPWO2004103403A1 (ja) | 2006-07-20 |
EP1637159A4 (en) | 2009-01-21 |
US20070274993A1 (en) | 2007-11-29 |
EP1637159A1 (en) | 2006-03-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2657133C (en) | Anti-human .alpha.9 integrin antibody and use of the same | |
KR101316990B1 (ko) | 항-α9 인테그린 항체와 그 용도 | |
JP6769948B2 (ja) | 移植拒絶の予防及び自己免疫疾患の治療に使用するための単離されたインターロイキン−34ポリペプチド | |
WO2004103403A1 (ja) | 免疫担当細胞活性化阻害剤およびその用途 | |
JP5736176B2 (ja) | 細胞外マトリックスタンパク質のアミノ酸配列rgdに特異的なヒト化抗体およびその使用 | |
JP5399710B2 (ja) | 細胞外マトリックスタンパク質のアミノ酸配列rgdに対する抗体およびその製法と用途 | |
KR20140043795A (ko) | 가용성 인테그린 α4 변이체 | |
Gibbs et al. | Anakinra (Kineret) in psoriasis and psoriatic arthritis: a single-center, open-label, pilot study | |
US20210393740A1 (en) | Ptprs and proteoglycans in rheumatoid arthritis | |
WO2009104388A1 (ja) | 膠原病の予防・治療剤 | |
KR20230140362A (ko) | 항-Fetuin-B 항체 및 해당 항체를 유효 성분으로 포함하는 근육질환의 예방, 치료 또는 개선용 조성물 | |
Oerlemans et al. | Differential expression of multidrug resistance-related proteins on monocyte-derived macrophages from rheumatoid arthritis patients | |
Roelofs et al. | Expression of Toll-like receptor (TLR) 2, TLR3, TLR4 and TLR7 is increased in rheumatoid arthritis synovium and regulates cytokine production by dendritic cells upon stimulation of TLR specific pathways | |
King et al. | Amelioration of joint inflammation by a PAR-2-specific monoclonal antibody | |
Kyburz et al. | Toll-like receptor expression in synovial fibroblasts and normal skin fibroblasts and induction of matrix metallo-proteinase expression by various Toll-like receptor ligands | |
Kinne et al. | Cytokine expression was assessed during antigen-induced arthritis in the synovial membrane, inguinal lymph node, and spleen using competitive RT-PCR and sandwich ELISA | |
Zhang et al. | Sustained downregulation of the TCRζ chain defines a transition from antigen mode to inflammation mode during terminal T-cell differentiation | |
Kelso et al. | Tryptase as a PAR-2 activator in joint inflammation | |
Rouster-Stevens et al. | Pharmacokinetic study of oral prednisolone compared with intravenous methylprednisolone in patients with vasculitis of rheumatic disease | |
Dell'Accio et al. | Molecular response to cartilage injury | |
van Oosterhout et al. | Arthroscopic lavage with methylprednisolone is superior compared with either treatment alone in patients with inflammatory arthritis of the knee: a randomized prospective trial | |
Smeets et al. | Identification of a natural soluble form of the IL-18 receptor accessory protein as an immunomodulator in experimental arthritis | |
Palmer et al. | Intracellular IL-1 receptor antagonist (icIL-1Ra1) does not antagonize growth inhibitory effects of pre-IL-1α in SaOS-2 cells | |
Bessis et al. | NKT cell status and IL-10-dependent therapeutic effect of NKT cell stimulation on collagen-arthritis in DBA/1 mice | |
Fearon et al. | Oncostatin M in rheumatoid arthritis: a key cytokine acts synergistically with other proinflammatory cytokines to promote human cartilage loss |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005506423 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004734385 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2004734385 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10557602 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 10557602 Country of ref document: US |